{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:08:25Z","timestamp":1786975705503,"version":"build-2736575974"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>In recent years, significant progress has been made in the pharmacologic treatment of heart failure (HF) with reduced ejection fraction (HFrEF), but there is still insufficient evidence for drug therapy for HF with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the outcomes associated with different drug combinations for the treatment of HFpEF and HFmrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A search of the PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases was conducted for studies published from inception to October 9, 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Randomized clinical trials on the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs), \u03b2-blockers, and sodium-glucose cotransporter 2 (SGLT2) inhibitors for patients with HFpEF or HFmrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>\n                      Data extraction and bias assessment were independently performed by 2 reviewers following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.equator-network.org\/reporting-guidelines\/prisma\/\">PRISMA<\/jats:ext-link>\n                      ) guideline. All data for 3 outcomes were pooled with a fixed-effect model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The main outcomes were first hospitalization for HF, all-cause mortality, and cardiovascular mortality. Hazard ratios (HRs) and 95% credible intervals (CrIs) were evaluated using a bayesian network meta-analysis model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this analysis, 19 randomized clinical trials, including 20\u202f633 patients with HF and an ejection fraction of 40% or more, without a remarkable risk of bias were included. Compared with placebo, no treatments were associated with a significant reduction in the risk of all-cause death or cardiovascular death. SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in the risk of HF hospitalization compared with placebo (SGLT2 inhibitors: HR, 0.71 [95% CrI, 0.60-0.83]; ARNIs: HR, 0.76 [95% CrI, 0.61-0.95]; MRAs: HR, 0.83 [95% CrI, 0.69-0.99]), and SGLT2 inhibitors were the optimal drug class in terms of reducing the risk for HF admission. Sensitivity analysis results demonstrated a progressive decrease in the risk of HF admission and an advance in mean rank associated with the increasing use of drug classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The findings of this study suggest that SGLT2 inhibitors were the optimal drug class for HFpEF and HFmrEF, consistent with the most recent guideline recommendation. The incremental use of combinations of SGLT2 inhibitors, ACE inhibitors or ARBs, and \u03b2-blockers may be associated with accumulative benefits in HF hospitalization rather than all-cause death among patients with HFpEF and HFmrEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.31963","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:01:32Z","timestamp":1663671692000},"page":"e2231963","source":"Crossref","is-referenced-by-count":41,"title":["Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction"],"prefix":"10.1001","volume":"5","author":[{"given":"Boyang","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"issue":"10100","key":"zoi220915r1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"zoi220915r2","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association.","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"issue":"36","key":"zoi220915r3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"zoi220915r4","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"zoi220915r5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.787810","article-title":"Comparative efficacy of medical treatments for chronic heart failure: a network meta-analysis.","volume":"8","author":"Xiang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"zoi220915r6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction.","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"zoi220915r7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi220915r8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"zoi220915r10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2288-10-54","article-title":"Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial.","volume":"10","author":"Woods","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"zoi220915r11","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019013","article-title":"Network meta-analysis: application and practice using R software.","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"issue":"1","key":"zoi220915r12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","article-title":"Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis.","volume":"10","author":"Burnett","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"7","key":"zoi220915r13","doi-asserted-by":"publisher","first-page":"A327","DOI":"10.1016\/j.jval.2014.08.595","article-title":"The importance of treatment classifications that account for concomitant treatments in the context of a network meta-analysis comparing pharmacological treatments for chronic heart failure.","volume":"17","author":"Burnett","year":"2014","journal-title":"Value Health"},{"key":"zoi220915r14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.707777","article-title":"Comparison of pharmacological treatment effects on long-time outcomes in heart failure with preserved ejection fraction: a network meta-analysis of randomized controlled trials.","volume":"12","author":"Lin","year":"2021","journal-title":"Front Pharmacol"},{"issue":"19","key":"zoi220915r15","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study.","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi220915r16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"17","key":"zoi220915r17","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi220915r18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction.","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"10025","key":"zoi220915r19","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0140-6736(16)00704-2","article-title":"A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.","volume":"387","author":"Hasenfu\u00df","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"zoi220915r20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","article-title":"One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: a randomized clinical trial.","volume":"3","author":"Shah","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"10330","key":"zoi220915r21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet"},{"key":"zoi220915r9","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796545\/xiang_2022_oi_220915_1663087733.39363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:01:35Z","timestamp":1663671695000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796545"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31963","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}